Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Johnson and Johnson

Last Updated: October 6, 2022

Details for Patent: 9,458,107

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 9,458,107 protect, and when does it expire?

Patent 9,458,107 protects STIVARGA and is included in one NDA.

This patent has fifty-five patent family members in thirty-eight countries.

Summary for Patent: 9,458,107
Title:Process for the preparation of 4-{4-[({[4 chloro-3-(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluorphenoxy-N-- ethylpyridie-carboxamide, its salts and monohydrate
Abstract: The present invention relates to a process for preparing 4-(4-[({[4-chloro-3-(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluo- rophenoxy)-N-methylpyridine-2-carboxamide, its salts and monohydrate.
Inventor(s): Stiehl; Juergen (Sprockhovel, DE), Heilmann; Werner (Wuppertal, DE), Logers; Michael (Wuppertal, DE), Rehse; Joachim (Leichlingen, DE), Gottfried; Michael (Wuppertal, DE), Wichmann; Saskia (Berlin, DE)
Application Number:14/252,850
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,458,107
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 9,458,107

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bayer Hlthcare STIVARGA regorafenib TABLET;ORAL 203085-001 Sep 27, 2012 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,458,107

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
10004022Apr 15, 2010

International Family Members for US Patent 9,458,107

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 081060 See Plans and Pricing
Argentina 116395 See Plans and Pricing
Australia 2011240113 See Plans and Pricing
Brazil 112012026117 See Plans and Pricing
Canada 2796238 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.